Amitriptyline/Perphenazine Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Amitriptyline/Perphenazine Availability in 2026

If your patients are reporting difficulty filling prescriptions for Amitriptyline/Perphenazine (formerly Etrafon, Triavil), you're likely seeing a pattern that extends beyond individual pharmacy stock-outs. While this combination medication is not listed on the FDA's formal drug shortage database, practical availability challenges are widespread — and they're affecting patient adherence and outcomes.

This briefing covers the current landscape, clinical implications, and actionable strategies for managing your patients' care.

Timeline: How We Got Here

Understanding the history of this drug's market trajectory helps contextualize today's availability issues:

• Original approval: Amitriptyline/Perphenazine was FDA-approved as a combination product for depression with anxiety, agitation, or psychotic features
• Brand discontinuation: All brand-name products — Etrafon (Schering), Triavil (Merck), and Duo-Vil — were discontinued over the past two decades as newer psychiatric medications gained market share
• Generic consolidation: The number of generic manufacturers producing this combination has dwindled to a handful, creating a fragile supply chain
• 2024-2026: Broader supply chain disruptions affecting older generics have compounded the issue, with intermittent stock-outs reported nationally at chain pharmacies

Prescribing Implications

The limited availability of Amitriptyline/Perphenazine has several clinical considerations for prescribers:

Adherence Risk

Patients unable to fill their prescription may experience treatment gaps. Given the pharmacology of both components — abrupt discontinuation of a TCA can cause withdrawal syndrome, while stopping a phenothiazine can precipitate rebound psychosis or agitation — these gaps carry meaningful clinical risk.

Therapeutic Substitution Challenges

Amitriptyline/Perphenazine occupies a niche in psychiatric pharmacotherapy. Patients maintained on this combination have often failed or not tolerated newer agents. Switching requires careful consideration of:

• Cross-taper protocols to avoid withdrawal and rebound symptoms
• Differences in receptor binding profiles between older phenothiazines and atypical antipsychotics
• The anticholinergic burden — relevant particularly for elderly patients already at risk (Beers Criteria)
• Patient tolerance and history of side effects with individual components

Prior Authorization Complexity

If you prescribe an alternative combination (e.g., Olanzapine/Fluoxetine), be prepared for potential prior authorization requirements. Many payers will require documentation of the supply issue and may mandate step therapy. Having a pharmacy stock verification from a tool like Medfinder for Providers can support your prior authorization submissions.

Current Availability Picture

Here's what we know about Amitriptyline/Perphenazine availability as of early 2026:

• FDA shortage status: Not listed on the formal drug shortage database
• Manufacturer status: Multiple generic manufacturers remain active, but production volumes are low relative to demand spikes
• Chain pharmacy stocking: Inconsistent — automated inventory systems at CVS, Walgreens, and Rite Aid may not routinely stock this product due to low fill volumes
• Independent pharmacy access: Generally better, as these pharmacies can order from multiple distributors with more flexibility
• Available strengths: 10 mg/2 mg, 10 mg/4 mg, 25 mg/2 mg, 25 mg/4 mg, and 50 mg/4 mg tablets — though not all strengths are equally available at all times

Cost and Access Considerations

Cost is generally not the primary barrier for this medication, but it's worth understanding the landscape:

• Generic cash price: $50 to $62 for 30 tablets (25 mg/2 mg) without insurance
• With discount cards: $49 to $57 for 30 tablets via GoodRx or SingleCare
• Insurance coverage: Typically covered on Tier 2 or Tier 3 formularies; copays range from $5 to $25
• No manufacturer savings programs: Because all brand names are discontinued, no copay cards or manufacturer coupons exist
• Patient assistance: General programs through NeedyMeds and RxAssist may help uninsured patients

For patients struggling with cost, point them to our savings guide for Amitriptyline/Perphenazine or our provider's guide to helping patients save money.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder for Providers offers real-time pharmacy stock information that you can use during patient visits. When a patient reports fill difficulty, you can:

1. Search for pharmacies with current Amitriptyline/Perphenazine stock
2. Send the prescription to a pharmacy that has it available
3. Document the availability issue for prior authorization purposes

Component Prescribing

The most reliable workaround for supply issues is prescribing Amitriptyline and Perphenazine as separate generic medications:

• Amitriptyline HCl: Available in 10, 25, 50, 75, 100, and 150 mg tablets — widely stocked at virtually all pharmacies
• Perphenazine: Available in 2, 4, 8, and 16 mg tablets — well-stocked at most pharmacies

This approach maintains the same pharmacological profile while dramatically improving fill rates. The trade-off is increased pill burden, which may affect adherence in some patients.

Alternative Regimens

When the combination or its individual components are not appropriate, consider:

• Olanzapine/Fluoxetine (Symbyax): FDA-approved for treatment-resistant depression; available as generic
• Nortriptyline + Quetiapine: Provides TCA antidepressant coverage with atypical antipsychotic augmentation
• Nortriptyline + Aripiprazole: Aripiprazole is FDA-approved for MDD augmentation with a more favorable metabolic profile
• Doxepin monotherapy: For patients whose primary indication is depression with anxiety/insomnia (no psychotic features)

See the patient-facing article on alternatives to Amitriptyline/Perphenazine for details you can share with patients.

Looking Ahead

The structural factors behind Amitriptyline/Perphenazine's limited availability — brand discontinuation, generic market consolidation, and low volume economics — are unlikely to resolve quickly. Providers should:

• Proactively discuss contingency plans with patients currently maintained on this medication
• Document supply issues in the medical record to support future prior authorization or formulary exception requests
• Consider preventive transitions to more readily available regimens for patients who are flexible and clinically stable enough to switch
• Use pharmacy stock tools like Medfinder to stay ahead of fill failures

Final Thoughts

Amitriptyline/Perphenazine remains a clinically valuable medication for a specific patient population, but its practical availability in 2026 requires active management from prescribers. By staying informed about the supply landscape, maintaining backup prescribing strategies, and leveraging tools like Medfinder for Providers, you can help ensure your patients don't experience dangerous gaps in their psychiatric care.

For step-by-step guidance on managing your patients' access to this medication, see our companion article: How to Help Your Patients Find Amitriptyline/Perphenazine in Stock.